

Robert Bissonnette

List of Publications by Citations

Source: <https://exaly.com/author-pdf/443932/robert-bissonnette-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

115
papers

4,302
citations

38
h-index

62
g-index

119
ext. papers

5,362
ext. citations

3.3
avg, IF

5.34
L-index

#	Paper	IF	Citations
115	Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. <i>British Journal of Dermatology</i> , 2008 , 158, 808-17	4	272
114	Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. <i>British Journal of Dermatology</i> , 2016 , 175, 902-911	4	263
113	Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 143, 155-172	11.5	246
112	A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2013 , 169, 137-45	4	156
111	Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. <i>British Journal of Dermatology</i> , 2020 , 183, 242-255	4	137
110	Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, 1535-45	4.6	137
109	Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2015 , 136, 351-9.e1	11.5	120
108	Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 1507-1514	4.6	119
107	Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2015 , 172, 1395-406	4	106
106	Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative. <i>Journal of Rheumatology</i> , 2015 , 42, 1767-80	4.1	88
105	Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. <i>Journal of the American Academy of Dermatology</i> , 2012 , 66, e33-45	4.5	69
104	Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema. <i>British Journal of Dermatology</i> , 2010 , 162, 420-6	4	68
103	Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. <i>Lancet, The</i> , 2008 , 371, 1337-42	4.0	67
102	The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study. <i>British Journal of Dermatology</i> , 2019 , 181, 733-742	4	63
101	Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). <i>British Journal of Dermatology</i> , 2015 , 173, 777-87	4	62
100	Effects of the tumor necrosis factor- α antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial. <i>Circulation: Cardiovascular Imaging</i> , 2013 , 6, 83-90	3.9	61
99	Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 851-61.e4	4.5	59

98	Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. <i>British Journal of Dermatology</i> , 2018 , 179, 844-852	4	59
97	Current status of photodynamic therapy in dermatology. <i>Dermatologic Clinics</i> , 1997 , 15, 507-19	4.2	58
96	Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019 , 23, 50-74	1.6	58
95	IL-4R β Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2020 , 140, 191-202.e7	4.3	57
94	TNF- α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 1638-1645	4.3	56
93	Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014 , 28, 1298-305	4.6	56
92	Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 144, 1011-1024	11.5	54
91	Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 99-105	4.5	54
90	Systemic photodynamic therapy with aminolevulinic acid induces apoptosis in lesional T lymphocytes of psoriatic plaques. <i>Journal of Investigative Dermatology</i> , 2002 , 119, 77-83	4.3	52
89	Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. <i>BMC Dermatology</i> , 2016 , 16, 15	2.1	51
88	A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2016 , 27, 332-8	2.8	48
87	Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial. <i>British Journal of Dermatology</i> , 2012 , 166, 853-60	4	48
86	A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2006 , 54, 472-8	4.5	47
85	Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 1402-8	4.6	44
84	Weekly topical application of methyl aminolevulinic acid followed by light exposure delays the appearance of UV-induced skin tumours in mice. <i>Archives of Dermatological Research</i> , 2002 , 294, 237-42	3.3	44
83	Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study. <i>British Journal of Dermatology</i> , 2019 , 181, 88-95	4	42
82	A double-blind study of tolerance and efficacy of a new urea-containing moisturizer in patients with atopic dermatitis. <i>Journal of Cosmetic Dermatology</i> , 2010 , 9, 16-21	2.5	42
81	Crisaborole and atopic dermatitis skin biomarkers: An inpatient randomized trial. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 144, 1274-1289	11.5	40

80	A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept. <i>Journal of Dermatological Treatment</i> , 2012 , 23, 261-7	2.8	40
79	Etanercept in the treatment of palmoplantar pustulosis. <i>Journal of Drugs in Dermatology</i> , 2008 , 7, 940-6	2.2	40
78	Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. <i>Journal of the American Academy of Dermatology</i> , 2010 , 63, 228-34	4.5	39
77	Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. <i>British Journal of Dermatology</i> , 2017 , 177, 1033-1042	4	38
76	Canadian hand dermatitis management guidelines. <i>Journal of Cutaneous Medicine and Surgery</i> , 2010 , 14, 267-84	1.6	38
75	Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian Psoriasis Expert Panel. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004 , 8, 321-337	1.6	38
74	Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 612-618.e6	4.5	37
73	Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study. <i>British Journal of Dermatology</i> , 2018 , 179, 853-862	4	37
72	Redefining treatment options in chronic hand eczema (CHE). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010 , 24 Suppl 3, 1-20	4.6	36
71	Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 714-721	4.5	35
70	Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 476-485	4.6	35
69	Efficacy and tolerability of topical tacrolimus ointment for the treatment of male genital psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2008 , 12, 230-4	1.6	32
68	Systemic photodynamic therapy with aminolaevulinic acid delays the appearance of ultraviolet-induced skin tumours in mice. <i>British Journal of Dermatology</i> , 2001 , 144, 1207-14	4	32
67	Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council. <i>Journal of Allergy and Clinical Immunology</i> , 2021 , 147, 1174-1190.e1	11.5	32
66	Protoporphyrin IX fluorescence kinetics in UV-induced tumours and normal skin of hairless mice after topical application of 5-aminolevulinic acid methyl ester. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2002 , 67, 11-7	6.7	31
65	Photodynamic therapy with 5-aminolevulinic acid induces apoptosis and caspase activation in malignant T cells. <i>Journal of Cutaneous Medicine and Surgery</i> , 2001 , 5, 8-13	1.6	31
64	The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 839-846	4.5	30
63	Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012 , 26, 1516-21	4.6	28

62	Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial. <i>Archives of Dermatology</i> , 2010 , 146, 446-9		28
61	Multiple large surface photodynamic therapy sessions with topical methylaminolaevulinate in PTCH heterozygous mice. <i>British Journal of Dermatology</i> , 2006 , 154, 740-2	4	27
60	Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 62-70	4.5	27
59	Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases that Appear to Be Distinct from Psoriasis Vulgaris. <i>PLoS ONE</i> , 2016 , 11, e0155215	3.7	26
58	Effect of adalimumab on sleep parameters in patients with psoriasis and obstructive sleep apnea: a randomized controlled trial. <i>Journal of Dermatological Treatment</i> , 2014 , 25, 57-60	2.8	23
57	Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway. <i>Journal of Dermatological Science</i> , 2017 , 85, 20-26	4.3	23
56	Randomized study comparing the efficacy and tolerance of a lipophilic hydroxy acid derivative of salicylic acid and 5% benzoyl peroxide in the treatment of facial acne vulgaris. <i>Journal of Cosmetic Dermatology</i> , 2009 , 8, 19-23	2.5	23
55	Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004 , 8, 321-37	1.6	23
54	Multiple Large-Surface Photodynamic Therapy Sessions with Topical or Systemic Aminolevulinic Acid and Blue Light in UV-Exposed Hairless Mice. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004 , 8, 131-139	1.6	23
53	Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 403-410	4.6	22
52	Photodynamic therapy with methylaminolevulinate 80 mg/g without occlusion improves acne vulgaris. <i>Journal of Drugs in Dermatology</i> , 2010 , 9, 1347-52	2.2	22
51	Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 33-39	4.5	21
50	Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne. <i>Journal of Cosmetic Dermatology</i> , 2011 , 10, 174-8	2.5	21
49	Identification of key research needs for topical therapy treatment of psoriasis - a consensus paper by the International Psoriasis Council. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, 1115-9	4.6	21
48	Comparison of UVA protection afforded by high sun protection factor sunscreens. <i>Journal of the American Academy of Dermatology</i> , 2000 , 43, 1036-8	4.5	19
47	Risk of myocardial infarction in canadian patients with psoriasis: a retrospective cohort study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2013 , 17, 398-403	1.6	18
46	Drug-induced toxic pustuloderma. <i>International Journal of Dermatology</i> , 1992 , 31, 172-4	1.7	18
45	Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study. <i>Dermatology and Therapy</i> , 2021 , 11, 571-585	4	18

44	Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 1707-1718.e9	4.3	16
43	Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary. <i>Journal of Rheumatology</i> , 2019 , 46, 751-754	4.1	14
42	Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study. <i>Clinical Pharmacology in Drug Development</i> , 2018 , 7, 524-531	2.3	14
41	Protection afforded by sunscreens containing inorganic sunscreens agents against blue light sensitivity induced by aminolevulinic acid. <i>Dermatologic Surgery</i> , 2008 , 34, 1469-76	1.7	14
40	Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis. <i>Journal of Drugs in Dermatology</i> , 2017 , 16, 1002-1013	2.2	14
39	Multiple large-surface photodynamic therapy sessions with topical or systemic aminolevulinic acid and blue light in UV-exposed hairless mice. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004 , 8, 131-9	1.6	13
38	Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section II: Tools for Assessing the Severity of Atopic Dermatitis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018 , 22, 10S-16S	1.6	13
37	Open-label exploratory study of acitretin for the treatment of severe chronic hand dermatitis. <i>Journal of Dermatological Treatment</i> , 2015 , 26, 373-5	2.8	12
36	Influence of the quantity of sunscreen applied on the ability to protect against ultraviolet-induced polymorphous light eruption. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2012 , 28, 240-3	2.4	11
35	Safety of conventional systemic agents and biologic agents in the treatment of psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009 , 13 Suppl 2, S67-76	1.6	11
34	Comparison of the ability of 2 sunscreens to protect against polymorphous light eruption induced by a UV-A/UV-B metal halide lamp. <i>Archives of Dermatology</i> , 1999 , 135, 1421-2		11
33	Major Differences in Expression of Inflammatory Pathways in Skin from Different Body Sites of Healthy Individuals. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 2228-2232.e10	4.3	9
32	Irradiance and light dose influence histological localization of photodamage induced by photodynamic therapy with aminolaevulinic acid. <i>British Journal of Dermatology</i> , 2004 , 151, 653-5	4	9
31	The Static Physician® Global Assessment of Genitalia: A Clinical Outcome Measure for the Severity of Genital Psoriasis. <i>Journal of Drugs in Dermatology</i> , 2017 , 16, 793-799	2.2	9
30	Increase in coronary atherosclerosis severity and the prevalence of coronary artery mixed plaques in patients with psoriasis. <i>British Journal of Dermatology</i> , 2017 , 176, 800-802	4	8
29	Chemopreventative thoughts for photodynamic therapy. <i>Dermatologic Clinics</i> , 2007 , 25, 95-100	4.2	8
28	Changes in serum free testosterone, sleep patterns, and 5-alpha-reductase type I activity influence changes in sebum excretion in female subjects. <i>Skin Research and Technology</i> , 2015 , 21, 47-53	1.9	7
27	Persistence of interleukin (IL)-17A+ T lymphocytes and IL-17A expression in treatment-resistant psoriatic plaques despite ustekinumab therapy. <i>British Journal of Dermatology</i> , 2017 , 177, 267-270	4	6

26	Vascular inflammation in moderate-to-severe atopic dermatitis is associated with enhanced Th2 response. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 , 76, 3107-3121	9.3	6
25	The AWARE study: methodology and baseline characteristics. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009 , 13 Suppl 3, S113-21	1.6	5
24	Persistence of Inflammatory Phenotype in Residual Psoriatic Plaques in Patients on Effective Biologic Therapy. <i>Journal of Investigative Dermatology</i> , 2020 , 140, 1015-1025.e4	4.3	5
23	Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section V: Consensus Statements on the Assessment and Management of Adult Patients With Moderate-to-Severe Atopic Dermatitis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018 , 22, 305-356	1.6	5
22	JAK inhibitors appear to have a bright future in the treatment of atopic dermatitis. <i>British Journal of Dermatology</i> , 2018 , 178, 321	4	4
21	Short incubation photodynamic therapy with methylaminolevulinate and no occlusion for the treatment of actinic keratoses. <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, 1386-7	4.5	4
20	Patterns of combination therapy with alefacept for the treatment of psoriasis in Canada in the AWARE study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009 , 13 Suppl 3, S131-8	1.6	4
19	Characterization of 57 kDa statin as a true marker for growth arrest in tissue by its disappearance from regenerating liver. <i>Journal of Cellular Physiology</i> , 1994 , 158, 277-84	7	4
18	Treatment of acne with photodynamic therapy. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2011 , 146, 445-56	0.8	4
17	Evidence Review of Topical Calcineurin Inhibitors for the Treatment of Adult Atopic Dermatitis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019 , 23, 5S-10S	1.6	3
16	Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 1576-81	4.6	3
15	A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis. <i>Dermatology and Therapy</i> , 2021 , 11, 2179-2193	4.93	3
14	Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018 , 22, 3S-5S	1.6	3
13	Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies-Executive Summary. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019 , 2, 149-152 ^{0.5}		2
12	Efficacy outcomes in patients using alefacept in the AWARE study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009 , 13 Suppl 3, S122-30	1.6	2
11	Incidence of cardiovascular events among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: pooled data from three large randomised clinical trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, e21-e24	4.6	2
10	Inflammatory Skin Disorders: Monocyte-Derived Cells Take Center Stage. <i>Frontiers in Immunology</i> , 2021 , 12, 691806	8.4	2
9	A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis.. <i>American Journal of Clinical Dermatology</i> , 2022 , 1	7.1	2

8	Use of capsule endoscopy to identify lesions suggestive of Crohn's disease in patients with moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 755-756	4.5	1
7	Chemoprevention of Skin Cancer with Photodynamic Therapy 2011 , 139-147		1
6	International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. <i>BMJ Open</i> , 2020 , 10, e039928	3	0
5	Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR. <i>Drug Safety</i> , 2021 , 44, 699-709	5.1	0
4	Response to Hjuler et al. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 2237-2238	4.3	
3	Multiple exposures to blue light does not improve psoriasis in patients with elevated endogenous levels of protoporphyrin IX. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2002 , 18, 104-104	2.4	
2	Ultraviolet B-induced immunosuppression is not associated with receptor activator of nuclear factor kappa B ligand upregulation in human skin. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2019 , 35, 47-50	2.4	
1	Prevention of polymorphous light eruption and solar urticaria. <i>Skin Therapy Letter</i> , 2002 , 7, 3-5	1.8	